To round up 2018, we asked our Expert panel to choose their top papers from across the year. Here, you can discover the articles they selected and read about and the reasons why!
In line with World AIDS Day this year we spoke to Andy Ustianowski (North Manchester General Hospital, UK) about the new challenges facing people living with HIV, including aging healthily and happily.
Declining HIV diagnoses in the UK have been highlighted in a recent report from Public Health England, meaning that for the first time UN targets have been reached.
Take a look behind the scenes of a recent Future Virology paper as we ask author Darrell Tan about the potential of pre-exposure prophylaxis (PrEP) for HIV prevention, PrEP failure and what research is needed in the field.
IDWeek: Could antiretroviral therapy efavirenz increase the risk of neurological conditions in offspring?
Antiretroviral therapy with efavirenz in HIV-positive pregnant women has been reported to increase the risk of neurological conditions in offspring.
State media has reported that the number of people living with HIV/AIDS has increased by 14% year-on-year.
A recent study carried out by researchers from the University of Zurich and University Hospital Zurich has discovered that the production of broad acting antibodies is dependent on the genome of the virus.
ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
Experimental HIV-1 vaccine regimen is safe and elicits a robust immune response according to results of a Phase I/IIa clinical trial.